MediciNova (NASDAQ:MNOV) plans to initiate a clinical trial of MN-166 (ibudilast) for acute respiratory distress syndrome caused by COVID-19.
The study will be conducted by Yale’s Advanced
Therapies Group. There are approx. 200 COVID-19 patients at Yale, with
34 on ventilators.
The trial will also allow investigators to
determine the optimal dose and route of administration in these very
critical patients.
https://seekingalpha.com/news/3559216-medicinova-to-launch-mnminus-166-trial-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.